{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T20:12:48Z","timestamp":1773173568069,"version":"3.50.1"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Among men with favorable-risk (ie, low-risk or favorable intermediate-risk) prostate cancer, confirmatory testing substantially improves the detection of aggressive cancers that may merit treatment instead of conservative management. Despite guideline recommendations, confirmatory testing is inconsistently used, and more than half of men do not receive it. Value-based interventions and payment incentives may improve care quality by motivating adherence to guideline-concordant care.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine the use of confirmatory testing among men with low-risk prostate cancer, after the application of a multifaceted intervention, which included physician education and a payment incentive, sponsored by a commercial payer to support its use.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study used data from the Michigan Urological Surgery Improvement Collaborative on men who received a diagnosis of low-risk prostate cancer between January 1, 2017, and July 1, 2022, with a minimum 6 months of follow-up. Statistical analysis was performed from October 2024 to June 2025.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Multifaceted intervention with a payment incentive, applied specifically to men who received a diagnosis of low-risk prostate cancer between April 1, 2018, and May 30, 2019. On meeting the payment incentive\u2019s benchmark (ie, \u226545% of men with low-risk prostate cancer complete confirmatory testing within 6 months of diagnosis), the insurer would distribute enhanced reimbursement on claims covered by commercial preferred provider organization plans.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Confirmatory testing completion (ie, magnetic resonance imaging before or after diagnostic biopsy, repeat prostate biopsy, or genomics test) relative to the preincentive period among men with low-risk prostate cancer. Secondary analyses examined practices by baseline confirmatory testing completion and proportion of patients with insurance plans covered by the insurer sponsoring the payment incentive.<\/jats:p><\/jats:sec>Results<\/jats:title>The study included 6609 patients (median age, 65 years [IQR, 60-70 years]), of whom 72.9% (n\u2009=\u20094818) elected for active surveillance. Confirmatory testing increased between 2017 (44.6% [725 of 1625]) and 2022 (64.3% [774 of 1203]) (P<\/jats:italic>\u2009&amp;lt;\u2009.001). During the payment incentive period, patients had a 7.5% (95% CI, 0.0%-15.4%; P<\/jats:italic>\u2009=\u2009.06) increase in the predicted probability of confirmatory testing completion relative to the preincentive period, although this change was not statistically significant (odds ratio, 1.43 [95% CI, 0.99-2.09]; P<\/jats:italic>\u2009=\u2009.06).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of men with prostate cancer, confirmatory testing completion improved over the study period. However, the payment incentive was not associated with a robust increase in its use. The results suggest collaboration between payers and physicians has the potential to improve measures of prostate cancer care quality, but also highlight the challenges associated with payment incentives and alternative payment model implementation.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.30624","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T15:31:28Z","timestamp":1757086288000},"page":"e2530624","source":"Crossref","is-referenced-by-count":1,"title":["A Payment Incentive to Improve Confirmatory Testing in Men With Prostate Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Arnav","family":"Srivastava","sequence":"first","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel R.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Addison","family":"Shay","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Oerline","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Massachusetts General Hospital, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preeti","family":"Chachlani","sequence":"additional","affiliation":[{"name":"Department of Urology, Massachusetts General Hospital, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Guro","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawson","family":"Hill","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Van Til","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Linsell","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Labardee","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Dall","sequence":"additional","affiliation":[{"name":"Department of Urology, Massachusetts General Hospital, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kassem S.","family":"Faraj","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avinash","family":"Maganty","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khurshid R.","family":"Ghani","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tudor","family":"Borza","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin B.","family":"Ginsburg","sequence":"additional","affiliation":[{"name":"Department of Urology, Wayne State University School of Medicine, Detroit, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent K.","family":"Hollenbeck","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahakn B.","family":"Shahinian","sequence":"additional","affiliation":[{"name":"Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"issue":"1","key":"zoi250862r1","first-page":"12","article-title":"Cancer statistics, 2024.","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"zoi250862r2","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/bju.14554","article-title":"Pathological upgrading at radical prostatectomy for patients with grade group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.","volume":"123","author":"Kaye","year":"2019","journal-title":"BJU Int"},{"issue":"3, pt 1","key":"zoi250862r3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.juro.2016.08.095","article-title":"Risk of pathological upgrading and up staging among men with low risk prostate cancer varies by race: results from the National Cancer Database.","volume":"197","author":"Maurice","year":"2017","journal-title":"J Urol"},{"key":"zoi250862r4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.urology.2017.06.014","article-title":"Prognostic significance of a negative confirmatory biopsy on reclassification among men on active surveillance.","volume":"107","author":"Ganesan","year":"2017","journal-title":"Urology"},{"issue":"2","key":"zoi250862r5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.juro.2015.02.015","article-title":"Incidence and predictors of upgrading and up staging among 10,000 contemporary patients with low risk prostate cancer.","volume":"194","author":"Dinh","year":"2015","journal-title":"J Urol"},{"issue":"6","key":"zoi250862r6","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1097\/JU.0000000000000713","article-title":"Long-term outcomes of active surveillance for prostate cancer: the Memorial Sloan Kettering Cancer Center experience.","volume":"203","author":"Carlsson","year":"2020","journal-title":"J Urol"},{"issue":"1","key":"zoi250862r7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and follow-up.","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"10","key":"zoi250862r8","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN Clinical Practice Guidelines in Oncology.","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"zoi250862r9","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.ijrobp.2021.01.014","article-title":"Receipt of guideline-recommended surveillance in a population-based cohort of prostate cancer patients undergoing active surveillance.","volume":"110","author":"Chen","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"zoi250862r10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.urology.2018.04.038","article-title":"Association between early confirmatory testing and the adoption of active surveillance for men with favorable-risk prostate cancer.","volume":"118","author":"Kaye","year":"2018","journal-title":"Urology"},{"issue":"3","key":"zoi250862r11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.juro.2016.02.2963","article-title":"How active is active surveillance? intensity of followup during active surveillance for prostate cancer in the United States.","volume":"196","author":"Loeb","year":"2016","journal-title":"J Urol"},{"issue":"6","key":"zoi250862r12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1097\/JU.0000000000001308","article-title":"Defining quality metrics for active surveillance: the Michigan Urological Surgery Improvement Collaborative experience.","volume":"204","author":"Ginsburg","year":"2020","journal-title":"J Urol"},{"key":"zoi250862r13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.urology.2020.07.067","article-title":"Impact of early confirmatory tests on upgrading and conversion to treatment in prostate cancer patients on active surveillance.","volume":"147","author":"Ginsburg","year":"2021","journal-title":"Urology"},{"issue":"11","key":"zoi250862r14","doi-asserted-by":"publisher","first-page":"846.e17","DOI":"10.1016\/j.urolonc.2020.07.008","article-title":"Concordance of confirmatory prostate biopsy in active surveillance with national guidelines: an analysis from the multi-institutional PURC cohort.","volume":"38","author":"Talwar","year":"2020","journal-title":"Urol Oncol"},{"issue":"1","key":"zoi250862r15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35633","article-title":"Commercial prices and their influence on urology practices: prostate cancer care among men with Medicare.","volume":"131","author":"Srivastava","year":"2025","journal-title":"Cancer"},{"issue":"1","key":"zoi250862r17","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00464-023-10498-9","article-title":"Use of statewide financial incentives to improve documentation of hernia and mesh characteristics in ventral hernia repair.","volume":"38","author":"O\u2019Neill","year":"2024","journal-title":"Surg Endosc"},{"issue":"5","key":"zoi250862r18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7326\/M16-1881","article-title":"The effects of pay-for-performance programs on health, health care use, and processes of care: a systematic review.","volume":"166","author":"Mendelson","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi250862r19","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6810","article-title":"Value-based payment models and management of newly diagnosed prostate cancer.","volume":"13","author":"Maganty","year":"2024","journal-title":"Cancer Med"},{"issue":"2","key":"zoi250862r20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/JU.0000000000002230","article-title":"Development and validation of models to predict pathological outcomes of radical prostatectomy in regional and national cohorts.","volume":"207","author":"\u00d6tles","year":"2022","journal-title":"J Urol"},{"issue":"10","key":"zoi250862r21","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jama.2020.13129","article-title":"Association between patient social risk and physician performance scores in the first year of the Merit-based Incentive Payment System.","volume":"324","author":"Khullar","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"zoi250862r23","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamasurg.2021.0979","article-title":"Use of telehealth by surgical specialties during the COVID-19 pandemic.","volume":"156","author":"Chao","year":"2021","journal-title":"JAMA Surg"},{"issue":"1","key":"zoi250862r24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.53658","article-title":"Physician payment incentives and active surveillance in low-risk prostate cancer.","volume":"8","author":"Srivastava","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi250862r25","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.juro.2017.07.085","article-title":"A roadmap for improving the management of favorable risk prostate cancer.","volume":"198","author":"Auffenberg","year":"2017","journal-title":"J Urol"},{"issue":"10","key":"zoi250862r26","doi-asserted-by":"publisher","first-page":"e863","DOI":"10.1200\/JOP.19.00088","article-title":"Practice-level adoption of conservative management for prostate cancer.","volume":"15","author":"Modi","year":"2019","journal-title":"J Oncol Pract"},{"issue":"19","key":"zoi250862r27","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis.","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi250862r28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","article-title":"Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study.","volume":"20","author":"Rouvi\u00e8re","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi250862r29","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","article-title":"Head-to-head comparison of transrectal ultrasound\u2013guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance\u2013guided biopsy in biopsy-na\u00efve men with elevated prostate-specific antigen: a large prospective multicenter clinical study.","volume":"75","author":"van der Leest","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"zoi250862r30","first-page":"20","article-title":"Is confirmatory biopsy still necessary for active surveillance of men with grade group 1 prostate cancer in the era of multiparametric MRI?","volume":"213","author":"Bhanji","year":"2025","journal-title":"J Urol"},{"key":"zoi250862r16","unstructured":"Huber? K, Gonzalez-Smith? J, Wang? A, . Engaging specialists in accountable care: tailoring payment models based on specialties and practice contexts. Health Affairs. December 21, 2023. Accessed July 17, 2025. https:\/\/www.healthaffairs.org\/content\/forefront\/engaging-specialists-accountable-care-tailoring-payment-models-based-specialties-and"},{"key":"zoi250862r22","unstructured":"Mehrotra? A, Chernew? ME, Linetsky? D, Hatch? H, Cutler? DM. The impact of the COVID-19 pandemic on outpatient visits: a rebound emerges. The Commonwealth Fund. May 19, 2020. Accessed October 7, 2024. https:\/\/www.commonwealthfund.org\/publications\/2020\/apr\/impact-covid-19-outpatient-visits"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2838515\/srivastava_2025_oi_250862_1756406184.34704.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T15:31:31Z","timestamp":1757086291000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2838515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.30624","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]}}}